A total of € 78.2 million was used for acquisitions and investments in other financial assets. Of this amount, € 6.9 million was used to acquire SeQuant AB, of Umea, Sweden, € 4.6 million to acquire
Litec-LLL GmbH of Greifswald, Germany, and € 30.2 million to acquire Bio-Fyt Pharma N.V., of
Sint-Jans-Molenbeek, Belgium. In addition, additional holdings in PT Merck Tbk of Jakarta, Indonesia, were acquired for € 10.2 million. Investments in other financial assets totaled € 26.3 million.
| XLS |
|
€ million |
SeQuant AB |
Litec-LLL GmbH |
PT Merck Tbk |
Bio-Fyt Pharma N.V. |
|
Purchase price |
6.9 |
5.6 |
10.2 |
32.6 |
|
Cash and cash equivalents acquired |
– |
–1.0 |
– |
–2.4 |
|
Net cash outflows |
6.9 |
4.6 |
10.2 |
30.2 |
There were no cash inflows from disposals of Group companies in 2008.
The decline in other financial assets is due to the withdrawal of € 497.9 million from a monetary investment for financing purposes.
back
